Full Press Release Details
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
New issue announcement,
application for quotation of additional securities
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become
ASX s property and may be made public.
Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01,
11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13
| Name of entity |
| Prima BioMed Ltd ( Company ) |
| ABN |
| 90 009 237 889 |
We (the entity) give ASX the following information.
You must complete the
relevant sections (attach sheets if there is not enough space).
| 1 | + Class of + securities issued or to be issued | Performance Rights | ||
| 2 | Number of + securities issued or to be issued (if known) or maximum number which may be issued | 38,183,211 | ||
| 3 | Principal terms of the + securities (e.g. if options, exercise price and expiry date; if partly paid + securities, the amount outstanding and due dates for payment; if + convertible securities, the conversion price and dates for conversion) | Performance Rights granted as Long Term Incentives ( LTIs ) and Short Term Incentives ( STIs ) have been issued under Executive Incentive Plan as follows: 1. 26,715,686 of Performance rights are granted as LTIs subject to meeting vesting conditions of total shareholder return criteria being achieved and continued employment till 1 October 2017 for 75% of these LTIs and till 1 October 2018 for 25% of these LTIs. 2. 11,467,525 of Performance rights are granted as STIs with vesting conditional on meeting various individually set KPIs and continued employment till 1 October 2015. On vesting of either LTIs or STIs, shares will be issued for no consideration. |
| 4 | Do the + securities rank equally in all respects from the + issue date with an existing + class of quoted + securities? If the additional + securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | Yes, if/when the Performance Rights vest to shares. | ||
| 5 | Issue price or consideration | Nil | ||
| 6 | Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) | Performance Rights are issued to employee under the Executive Incentive Plan. | ||
| 6a | Is the entity an + eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b 6h in relation to the + securities the subject of this Appendix 3B , and comply with section 6i | No. | ||
| 6b | The date the security holder resolution under rule 7.1A was passed | N/A. | ||
| 6c | Number of + securities issued without security holder approval under rule 7.1 | N/A. | ||
| 6d | Number of + securities issued with security holder approval under rule 7.1A | N/A. |
| 6e | Number of + securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | N/A | ||
| 6f | Number of + securities issued under an exception in rule 7.2 | N/A. | ||
| 6g | If + securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the + issue date and both values. Include the source of the VWAP calculation. | N/A. | ||
| 6h | If + securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements | N/A. | ||
| 6i | Calculate the entity s remaining issue capacity under rule 7.1 and rule 7.1A complete Annexure 1 and release to ASX Market Announcements | N/A. |
| 7 | + Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. | 19 September 2014 | ||||||||
| Number | + Class | |||||||||
| 8 | Number and + class of all + securities quoted on ASX ( including the + securities in section 2 if applicable) | 1,228,709,341 77,378,696 | Ordinary fully paid shares (ASX: PRR) Options exercisable at $0.20 on or before 19 June 2017 (PRRO) | |||||||
| 9 | Number and + class of all | Number | +Class - Options | |||||||
| + securities not quoted on ASX ( including the + securities in | Amount | Exercise Price | Expiration Date | |||||||
| 1,884,253 | $0.2685 | 9 November 2014 | ||||||||
| section 2 if applicable) | 1,884,253 | $0.2360 | 8 December 2014 | |||||||
| 1,061,411 | $0.2271 | 12 January 2015 | ||||||||
| 1,118,211 | $0.2345 | 12 February 2015 | ||||||||
| 1,075,269 | $0.2277 | 18 March 2015 |
| 500,000 | $0.2500 | 6 May 2015 | ||||||||
| 1,055,011 | $0.2351 | 19 May 2015 | ||||||||
| 2,000,000 | $0.1000 | 6 December 2014 | ||||||||
| 740,741 | $0.3390 | 1 February 2016 | ||||||||
| 100,000 | $0.2790 | 3 November 2014 | ||||||||
| 100,000 | $0.2329 | 3 January 2015 | ||||||||
| 2,800,000 | $0.1850 | 1 August 2015 | ||||||||
| 200,000 | $0.1730 | 20 February 2016 | ||||||||
| 1,758,176 | $0.0774 | 30 June 2018 | ||||||||
| 165,116 | $0.0774 | 30 June 2018 | ||||||||
| 16,442,441 | Total | |||||||||
| Number | +Class Performance Rights | |||||||||
| Amount | Type | Expiration Date | ||||||||
| 11,467,525 | STI | 30 October 2015 | ||||||||
| 26,715,686 | LTI | 30 October 2018 | ||||||||
| 38,183,211 | Total | |||||||||
| 10 | Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) | Unchanged | ||||||||
| Part 2 - Pro rata issue | ||||||||||
| 11 | Is security holder approval required? | N/A. | ||||||||
| 12 | Is the issue renounceable or non-renounceable? | N/A. | ||||||||
| 13 | Ratio in which the + securities will be offered | N/A. | ||||||||
| 14 | + Class of + securities to which the offer relates | N/A. | ||||||||
| 15 | + Record date to determine entitlements | N/A. | ||||||||
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | N/A. | ||||||||
| 17 | Policy for deciding entitlements in relation to fractions | N/A. |
| 18 | Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. | N/A. | ||
| 19 | Closing date for receipt of acceptances or renunciations | N/A. | ||
| 20 | Names of any underwriters | N/A. | ||
| 21 | Amount of any underwriting fee or commission | N/A. | ||
| 22 | Names of any brokers to the issue | N/A. | ||
| 23 | Fee or commission payable to the broker to the issue | N/A. | ||
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders | N/A. | ||
| 25 | If the issue is contingent on security holders approval, the date of the meeting | N/A. | ||
| 26 | Date entitlement and acceptance form and offer documents will be sent to persons entitled | N/A. | ||
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | N/A. | ||
| 28 | Date rights trading will begin (if applicable) | N/A. | ||
| 29 | Date rights trading will end (if applicable) | N/A. | ||
| 30 | How do security holders sell their entitlements in full through a broker? | N/A. | ||
| 31 | How do security holders sell part of their entitlements through a broker and accept for the balance? | N/A. |
| 32 | How do security holders dispose of their entitlements (except by sale through a broker)? | N/A. | ||
| 33 | + Issue date | N/A. |
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities
| 34 | Type of + securities ( tick one ) | |||
| (a) | + Securities described in Part 1 | |||
| (b) | All other + securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities |
Entities that have ticked box 34(a)
Additional securities forming a new class of securities
Tick to indicate you are
providing the information or documents
| 35 | If the + securities are + equity securities, the names of the 20 largest holders of the additional + securities, and the number and percentage of additional + securities held by those holders | |||
| 36 | If the + securities are + equity securities, a distribution schedule of the additional + securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over | |||
| 37 | A copy of any trust deed for the additional + securities |
Entities that have ticked box 34(b)
| 38 | Number of + securities for which + quotation is sought | |||
| 39 | + Class of + securities for which quotation is sought |
| 41 | Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another + security, clearly identify that other + security) | |||||
| Number | + Class | |||||
| 42 | Number and + class of all + securities quoted on ASX ( including the + securities in clause 38) |
| Sign here: | Date: | 19 September 2014 | ||||||
| Company secretary | ||||||||
| Print name: | Deanne Miller |